Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poly-ICLC-matured dendritic cells
- Development stage
- Unknown
- Lead developer
- Oncovir
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
Poly-ICLC-matured dendritic cells are an investigational autologous cell-based immunotherapy. The therapeutic process involves harvesting a patient's monocytes, differentiating them into dendritic cells, and loading them with specific tumor-associated antigens (such as NY-ESO-1, Melan-A, hTERT, CEA, or autologous tumor lysate). These cells are then matured ex vivo using Poly-ICLC (Hiltonol), a stabilized double-stranded RNA analogue that acts as a potent agonist for Toll-like receptor 3 (TLR-3) and MDA-5. This maturation step is critical for enhancing the dendritic cells' ability to present antigens and secrete pro-inflammatory cytokines. Once re-administered to the patient, typically via intradermal injection, these matured dendritic cells activate cytotoxic T lymphocytes and natural killer (NK) cells to mount a targeted anti-tumor immune response. This platform has been evaluated in Phase I and Phase II clinical trials for various malignancies, including glioblastoma, melanoma, and pancreatic cancer.
- Other names
- Poly-ICLC-matured DC vaccineHiltonol-matured dendritic cellsPoly-ICLC-matured autologous dendritic cells
02
Targets
RLR (RIG-I-like receptors)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on poly-ICLC-matured dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poly-ICLC-matured dendritic cells.